14 Juli 2020
BioVersys and Partners from Lille Sign Long-term Collaboration Agreement Creating a Unique Cross-Border AMR Cluster in Antimicrobial Research Excellence
BioVersys and partners, the Institut Pasteur de Lille and the University of Lille, from Région Hauts-de-France, sign a long-term collaboration agreeme...
23 Juni 2020
BioVersys Receives QIDP Designation from the U.S. FDA for the Development of a fixed combination of BVL-GSK098 and ETH
Basel, Switzerland. June, 23rd, 2020. 09:00 CEST BioVersys develops BVL-GSK098, in collaboration with GSK, as an entirely new mechanism to poten...
05 Mai 2020
GARDP signs MOU with Swiss biotech BioVersys AG
The Global Antibiotic Research and Development Partnership (GARDP) has today announced an agreement with Swiss biopharmaceutical company BioVersys to...
04 Nov. 2019
BioVersys Receives CARB-X Award of up to US$ 8.92 Million
CARB-X funds BioVersys up to US$ 8.92 million to support the development of first-in-class anti-virulence small molecule drugs that disarm bacteria, o...
Recent Media Feeds
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
